Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.
News|Articles|October 29, 2012
Discontinuation of warfarin therapy higher than generally anticipated
Among older adults with atrial fibrillation (AF), persistence with warfarin therapy is generally lower than what has been reported in clinical trials, according study online in Archives of Internal Medicine.
Advertisement
Advertisement
Related to this article
StarkRx has launched as a modular, cost-plus pharmacy benefit management company for self-funded employers using Judi Health’s PBM, Judi Rx, to administer claims.
Part D enrollment has shifted: standalone plan offerings are down 22%, while special needs plans grew 21%, reshaping competition among fewer, larger sponsors nationally, finds an analysis by IPD Analytics.
ProAct Chief Operating Offier Deborah Dempsey says plan sponsors still lack the data and visibility to know whether they were shorted on a 340B claim.
AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.
OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point drop in body mass index and improved mental health.
Yellow eyelid Xanthelasma signals hidden high cholesterol and cardiovascular disease risk, tripling heart attack and stroke odds; Negin Yavari, M.D., and her team urge screening.
Maladaptive coping at baseline raised relapse and symptom risk over 12 months in first episode psychosis, King's College London researchers found.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Navitus launches GLP-1 drug management programs
2
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
3
Deborah Dempsey, Pharm.D., MBA, RPh, on 340B discounts vs. rebates | PBMI 2026
4
Judi Health, Employers Health team up to launch new PBM solution
5